X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4917) 4917
Book Review (1406) 1406
Publication (450) 450
Newsletter (40) 40
Book Chapter (34) 34
Conference Proceeding (18) 18
Book / eBook (10) 10
Dissertation (8) 8
Newspaper Article (5) 5
Magazine Article (4) 4
Transcript (4) 4
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4150) 4150
humans (2734) 2734
animals (2253) 2253
endothelin (2209) 2209
male (1927) 1927
endothelin receptor antagonists (1408) 1408
pharmacology & pharmacy (1204) 1204
rats (1120) 1120
female (1104) 1104
hypertension (802) 802
hypertension, pulmonary - drug therapy (800) 800
pulmonary hypertension (715) 715
antihypertensive agents - therapeutic use (683) 683
middle aged (638) 638
endothelin-1 (633) 633
cardiac & cardiovascular systems (632) 632
sulfonamides - therapeutic use (632) 632
bosentan (631) 631
adult (507) 507
treatment outcome (505) 505
expression (480) 480
rats, sprague-dawley (473) 473
endothelin receptor antagonist (442) 442
endothelin-1 - metabolism (442) 442
abridged index medicus (441) 441
endothelin a receptor antagonists (410) 410
aged (406) 406
nitric oxide (405) 405
hypertension, pulmonary - physiopathology (397) 397
disease models, animal (392) 392
physiology (384) 384
nitric-oxide (377) 377
mice (367) 367
pulmonary arterial hypertension (367) 367
research (362) 362
respiratory system (362) 362
cells (359) 359
therapy (349) 349
analysis (345) 345
care and treatment (345) 345
blood pressure - drug effects (344) 344
dose-response relationship, drug (343) 343
endothelium (336) 336
rodents (332) 332
rats, wistar (312) 312
peripheral vascular disease (311) 311
double-blind (305) 305
drug therapy (292) 292
endothelin-1 - pharmacology (276) 276
sulfonamides - pharmacology (275) 275
health aspects (274) 274
disease (272) 272
physiological aspects (271) 271
medicine & public health (270) 270
heart failure (267) 267
time factors (263) 263
survival (258) 258
blood-pressure (257) 257
receptor, endothelin a (257) 257
receptor, endothelin a - metabolism (254) 254
endothelin-1 - physiology (244) 244
receptors, endothelin - metabolism (243) 243
hypertension, pulmonary - etiology (242) 242
vasodilator agents - therapeutic use (240) 240
drug therapy, combination (239) 239
endothelin 1 (239) 239
vasoconstriction - drug effects (238) 238
endothelin-receptor antagonist (236) 236
in vitro techniques (234) 234
receptor (229) 229
blood pressure (227) 227
rat (227) 227
vasoconstriction (225) 225
endothelin receptor antagonists - therapeutic use (223) 223
endothelins - physiology (220) 220
receptors (218) 218
endothelin-1 - blood (214) 214
peptides, cyclic - pharmacology (213) 213
receptor antagonist (210) 210
inflammation (209) 209
pulmonary arterial-hypertension (209) 209
pyrimidines - therapeutic use (209) 209
medicine, research & experimental (208) 208
endothelins - pharmacology (207) 207
nitric-oxide synthase (206) 206
endothelins - metabolism (205) 205
hypertension - drug therapy (205) 205
surgery (205) 205
hemodynamics (200) 200
arterial-hypertension (199) 199
urology & nephrology (199) 199
antihypertensive agents - pharmacology (197) 197
hemodynamics - drug effects (195) 195
prostacyclin (195) 195
heart (194) 194
medicine, general & internal (194) 194
biochemistry & molecular biology (193) 193
risk factors (193) 193
proteins (191) 191
heart failure - drug therapy (190) 190
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4816) 4816
German (48) 48
French (45) 45
Japanese (33) 33
Spanish (19) 19
Chinese (10) 10
Polish (8) 8
Russian (8) 8
Hungarian (3) 3
Italian (3) 3
Turkish (3) 3
Portuguese (2) 2
Swedish (2) 2
Danish (1) 1
Dutch (1) 1
Hebrew (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Experimental Eye Research, ISSN 0014-4835, 11/2018, Volume 176, pp. 1 - 9
Hypertension is an independent risk factor for diabetic retinopathy, yet anti-hypertensive medications such as blockade of angiotensin II do not completely... 
Hypertension | Diabetic retinopathy | Endothelin | VEGF | Diabetes | Vascular leakage | Retinal pigment epithelium | CELLS | ACTIVATION | ANGIOGENESIS | PREVALENCE | MODEL | DISEASE | OPHTHALMOLOGY | GROWTH-FACTOR | EXPRESSION | PROGRESSION | RETINAL-PIGMENT EPITHELIUM | Retinal Pigment Epithelium - metabolism | Retina - metabolism | Intravitreal Injections | Streptozocin | Rats, Inbred WKY | Ocular Hypertension - metabolism | Blood-Retinal Barrier - drug effects | Oligopeptides - therapeutic use | Ocular Hypertension - prevention & control | Endothelin A Receptor Antagonists - metabolism | Diabetes Mellitus, Experimental - prevention & control | Endothelin-2 - genetics | Blood Pressure - drug effects | Endothelin-2 - metabolism | Real-Time Polymerase Chain Reaction | Endothelin A Receptor Antagonists - therapeutic use | Fluorescent Antibody Technique, Indirect | Rats, Inbred SHR | Endothelin B Receptor Antagonists - therapeutic use | Choroid - metabolism | Enzyme-Linked Immunosorbent Assay | Endothelin-1 - genetics | Endothelin-1 - metabolism | Rats | Endothelin B Receptor Antagonists - metabolism | Antihypertensive Agents - therapeutic use | Diabetic Retinopathy - metabolism | Diabetic Retinopathy - prevention & control | Animals | Piperidines - therapeutic use | Peptides, Cyclic - therapeutic use | Endothelial growth factors | RNA | Angiotensin | Endothelium | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1829 - 1835
Aim: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the... 
diabetic kidney disease | endothelin receptor antagonist | precision medicine | randomized controlled clinical trial | atrasentan | KIDNEY-DISEASE | DAPAGLIFLOZIN | ALBUMINURIA | ENDOCRINOLOGY & METABOLISM | DIABETIC-NEPHROPATHY | EMPAGLIFLOZIN | Humans | Middle Aged | Hypertension - drug therapy | Male | Risk | Renal Insufficiency - prevention & control | Renal Insufficiency - epidemiology | Drug Therapy, Combination - adverse effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Diabetic Angiopathies - complications | Endothelin A Receptor Antagonists - adverse effects | Female | Renal Insufficiency - complications | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Precision Medicine | Double-Blind Method | Diabetic Angiopathies - drug therapy | Antihypertensive Agents - therapeutic use | Diabetic Nephropathies - complications | Atrasentan - therapeutic use | Hypertension - complications | Diuretics - therapeutic use | Aged | Diabetic Nephropathies - epidemiology | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Albumin | Endothelin | Kidney diseases | Natriuretic peptides | Creatinine | Brain natriuretic peptide | Kidneys | Sodium | Epidermal growth factor receptors | Diabetes mellitus | Blood pressure | Diabetes mellitus (non-insulin dependent) | Patients | Glomerular filtration rate | Index Medicus | Clinical Trial Design
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1369 - 1376
Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative,... 
diabetic kidney disease | endothelin receptor antagonist | randomized controlled clinical trial | atrasentan | personalized medicine | INHIBITION | ALBUMINURIA | PREDICTORS | HEART-FAILURE | ENDOCRINOLOGY & METABOLISM | Humans | Diabetic Nephropathies - drug therapy | Male | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - drug therapy | Drug Therapy, Combination - adverse effects | Diabetic Nephropathies - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adult | Endothelin A Receptor Antagonists - adverse effects | Female | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Kidney - physiopathology | Precision Medicine | Severity of Illness Index | Kidney - drug effects | Double-Blind Method | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Randomized Controlled Trials as Topic | Kidney Failure, Chronic - prevention & control | Kidney Failure, Chronic - complications | Atrasentan - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Research Design | Type 2 diabetes | Antimitotic agents | Medical research | Endothelin | Chronic kidney failure | Diabetic nephropathies | Angiotensin | Clinical trials | Albumin | Medicine, Experimental | Antineoplastic agents | Risk factors | Creatinine | Renin | Nephropathy | Kidneys | Diabetes mellitus | Diabetes | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Patients | Index Medicus | Clinical Trial Design
Journal Article
Brazilian Journal of Medical and Biological Research, ISSN 0100-879X, 2018, Volume 51, Issue 2, pp. e6373 - e6373
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2019 - 2022
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium... 
pharmacokinetics | endothelin receptor antagonist | dose‐finding | pharmacodynamics | diabetic nephropathy | dose-finding | ENDOCRINOLOGY & METABOLISM | DIABETIC-NEPHROPATHY | AVOSENTAN | Biomarkers - urine | Humans | Body Weight - drug effects | Diabetic Nephropathies - drug therapy | Diabetic Nephropathies - blood | Sodium - metabolism | Dose-Response Relationship, Drug | Drug Therapy, Combination - adverse effects | Diabetic Nephropathies - physiopathology | Renal Insufficiency - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Endothelin A Receptor Antagonists - adverse effects | Renal Insufficiency - complications | Renal Insufficiency - drug therapy | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Diabetic Nephropathies - urine | Severity of Illness Index | Double-Blind Method | Endothelin A Receptor Antagonists - administration & dosage | Endothelin A Receptor Antagonists - pharmacokinetics | Biological Variation, Population | Renal Elimination - drug effects | Renal Insufficiency - metabolism | Albuminuria - prevention & control | Atrasentan - therapeutic use | Metabolic Clearance Rate - drug effects | Atrasentan - administration & dosage | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Atrasentan - pharmacokinetics | Type 2 diabetes | Antimitotic agents | Medical research | Evaluation | Endothelin | Analysis | Diabetic nephropathies | Albumin | Medicine, Experimental | Antineoplastic agents | Creatinine | Kidneys | Sodium | Diabetes mellitus (non-insulin dependent) | Diabetes mellitus | Index Medicus | Brief Reports | Brief Report
Journal Article
Journal Article
Journal Article
by Heerspink, Hiddo J L and Parving, Hans-Henrik and Andress, Dennis L and Bakris, George and Correa-Rotter, Ricardo and Hou, Fan-Fan and Hou, Fanfan and Kitzman, Dalane W and Kohan, Donald and Makino, Shinya and Makino, Hirofumi and McMurray, John J V and Melnick, Joel Z and Miller, Michael G and Miller, Alan and Miller, Steven and Pergola, Pablo E and Pergola, Pablo and Perkovic, Vlado and Tobe, Sheldon and Yi, Joo Hark and Yi, Tingting and Wigderson, Melissa and de Zeeuw, Dick and Elbert, Alicia and Vallejos, Augusto and Alvarisqueta, Andres and Maffei, Laura and Juncos, Luis and de Arteaga, Javier and Greloni, Gustavo and Farias, Eduardo and Zucchini, Alfredo and Vogel, Daniel and Cusumano, Ana and Santos, Juan and Fraenkel, Margaret and Gallagher, Martin and Davis, Tim and Acharya, Shamasunder and Cooke, Duncan and Suranyi, Michael and Roger, Simon and Toussaint, Nigel and Pollock, Carol and Chan, Doris and Stranks, Stephen and MacIsaac, Richard and Endre, Zoltan and Schmidt, Alice and Schmidt, Rebecca and Prager, Rudolf and Mayer, Gert and Warling, Xavier and Jadoul, Michel and Hougardy, Jean and Vercammen, Chris and Van Vlem, Bruno and Gillard, Pieter and Costa e Forti, Adriana and Borges, Joao Lindolfo and Santos Canani, Luis and Eliaschewitz, Freddy and Leite, Silmara and Fraige Filho, Fadlo and Paschoalin, Raphael and Moura Neto, Jose Andrade and Deboni, Luciane and de Lourdes Noronha, Irene and Cercato, Cintia and Prompt, Carlos Alberto and Zanella, Maria and Rassi, Nelson and D'Avila, Domingos and Milagres, Rosangela and Felicio, Joao and Pecoits Filho, Roberto and Riella, Miguel Carlos and Salles, Joao and Keitel, Elizete and Draibe, Sergio and Amodeo, Celso and Youmbissi, Joseph and Roy, Louise and Cournoyer, Serge and Jolly, Shivinder and Pichette, Vincent and Nesrallah, Gihad and Bajaj, Harpreet Singh and Khandwala, Hasnain and Aronson, Ronnie and Goluch, Richard and Tam, Paul and Rabbat, Christian and Bailey, Gordon and Chow, Stephen and Castillo, Alvaro and Danin Vargas, Alfredo and Gonzalez, Fernando and Munoz, Rodrigo and ... and SONAR Comm Investigators and SONAR Committees and Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1937 - 1947
Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | ENDOTHELIN | ALBUMINURIA | NEPHROPATHY | Humans | Middle Aged | Male | Diabetic Nephropathies - blood | Serum Albumin, Human - urine | Young Adult | Aged, 80 and over | Adult | Female | Diabetic Nephropathies - prevention & control | Endothelin A Receptor Antagonists - therapeutic use | Diabetic Nephropathies - urine | Glomerular Filtration Rate | Double-Blind Method | Endothelin A Receptor Antagonists - administration & dosage | Administration, Oral | Treatment Outcome | Creatinine - urine | Renal Insufficiency, Chronic - blood | Renal Insufficiency, Chronic - prevention & control | Atrasentan - therapeutic use | Creatinine - blood | Aged | Atrasentan - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Renal Insufficiency, Chronic - urine | Short term | Enrichment | End-stage renal disease | Renal function | Endothelin | Heart attacks | Peptides | Clinical trials | Cardiovascular disease | Transplantation | Retention | Randomization | Renin | Motivation | Hemoglobin | Blood pressure | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Heart failure | Urine | Creatinine | Enzymes | Kidneys | Epidermal growth factor receptors | Anemia | Diabetes mellitus | Health risks | Patients | Disease control | Glomerular filtration rate | Sodium | Angiotensin | Renal failure | Dialysis | Kidney diseases | Diabetes | Surface area | Potassium | Kidney transplantation | Long-term effects | Index Medicus | Abridged Index Medicus
Journal Article